Inventor
KINSELLA TODD M
US28 patents
⚠️ This page may combine multiple inventors who share the name “KINSELLA TODD M”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
RIGEL PHARMACEUTICALS INC
22 patentsUS7105341B2Sep 12, 2006
In vivo production of cyclic peptides
RIGEL PHARMACEUTICALS INC22 citations92
US7252952B2Aug 7, 2007
In vivo production of cyclic peptides for inhibiting protein—protein interaction
RIGEL PHARMACEUTICALS INC19 citations90
US7208571B2Apr 24, 2007
In vivo production of cyclic peptides
RIGEL PHARMACEUTICALS INC8 citations73
US6979549B2Dec 27, 2005
Methods of identifying compounds that modulate IL-4 receptor-mediated IgE synthesis utilizing a CLLD8 protein
RIGEL PHARMACEUTICALS INC5 citations73
US7378248B2May 27, 2008
In vivo production of cyclic peptides for inhibiting protein-protein interaction
RIGEL PHARMACEUTICALS INC7 citations72
US7056687B2Jun 6, 2006
Methods and compositions for screening for altered cellular phenotypes
RIGEL PHARMACEUTICALS INC4 citations70
US7566765B2Jul 28, 2009
Heterocyclic compounds containing a nine-membered carbon-nitrogen ring
RIGEL PHARMACEUTICALS INC4 citations62
US7425418B2Sep 16, 2008
Compounds that modulate processes associated with IgE production
RIGEL PHARMACEUTICALS INC3 citations62
US7378251B2May 27, 2008
Methods of identifying compounds that modulate IL-4 receptor-mediated IgE synthesis utilizing a thioredoxin-like 32 kDa protein
RIGEL PHARMACEUTICALS INC2 citations62
US7060433B1Jun 13, 2006
Methods and compositions for screening using diphtheria toxin constructs
RIGEL PHARMACEUTICALS INC2 citations62
US7872096B2Jan 18, 2011
Methods for cyclizing synthetic polymers
RIGEL PHARMACEUTICALS INC0 citations51
US7604951B2Oct 20, 2009
Method for identifying compounds that modulate RXR associated processes with IgE production
RIGEL PHARMACEUTICALS INC1 citations51
US7598050B2Oct 6, 2009
Methods of identifying compounds that modulate IL-4 receptor-mediated IgE synthesis utilizing a chloride intracellular channel 1 protein
RIGEL PHARMACEUTICALS INC1 citations51
US7563585B2Jul 21, 2009
Methods of assaying compounds that modulate IL-4 receptor-mediated IgE synthesis utilizing a thioredoxin-like 32 kDa protein (TXNL)
RIGEL PHARMACEUTICALS INC0 citations51
US7422867B2Sep 9, 2008
Methods of identifying compounds that modulate IL-4 receptor mediated IgE synthesis utilizing a CLLD8 protein
RIGEL PHARMACEUTICALS INC0 citations51
US7374894B2May 20, 2008
Methods of identifying compounds that modulate IL-4 receptor-mediated IgE synthesis utilizing a chloride intracellular channel 1 protein
RIGEL PHARMACEUTICALS INC0 citations51
US7241581B2Jul 10, 2007
Methods of identifying compounds that modulate IL-4 receptor-mediated IgE synthesis utilizing a c-MYC protein
RIGEL PHARMACEUTICALS INC0 citations51
US7208289B2Apr 24, 2007
Methods of identifying compounds that modulate IL-4 receptor mediated IgE synthesis utilizing a CLLD8 protein
RIGEL PHARMACEUTICALS INC0 citations51
US7189523B2Mar 13, 2007
Methods of identifying compounds that modulate IL-4 receptor-mediated IgE synthesis utilizing a B-cell associated protein
RIGEL PHARMACEUTICALS INC0 citations51
US7141434B2Nov 28, 2006
Methods of identifying compounds that modulate IL-4 receptor-mediated IgE synthesis utilizing an adenosine kinase
RIGEL PHARMACEUTICALS INC0 citations51
US11104737B2Aug 31, 2021
ACVR2A-specific antibody and method of treatment of muscle atrophy
RIGEL PHARMACEUTICALS INC0 citations47
US7863222B2Jan 4, 2011
shRNA library
RIGEL PHARMACEUTICALS INC0 citations41